Alpha-synucleinopathies refer to a class of neurodegenerative disorders characterized by the abnormal aggregation and deposition of the protein alpha-synuclein (α-syn) within the central and peripheral nervous systems[@spillantini1997]. This pathological protein accumulation manifests as intracellular inclusions known as Lewy bodies, glial cytoplasmic inclusions, or neuronal processes, depending on the specific disease entity[@goedert2019]. The spectrum of alpha-synucleinopathies includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF)[@mccann2014].
Alpha-synuclein is a 140-amino acid protein encoded by the SNCA gene, predominantly expressed in presynaptic terminals of neurons throughout the brain[@burre2018]. Under physiological conditions, α-syn exists as a soluble, natively unfolded protein that participates in synaptic vesicle regulation, neurotransmitter release, and neuronal plasticity[@cabin2002]. However, in pathological states, α-syn undergoes a conformational transformation from its native unfolded state into beta-sheet-rich fibrillar aggregates that form the core constituent of disease-defining inclusions[@conway1998].
Alpha-synucleinopathies refer to a class of neurodegenerative disorders characterized by the abnormal aggregation and deposition of the protein alpha-synuclein (α-syn) within the central and peripheral nervous systems[@spillantini1997]. This pathological protein accumulation manifests as intracellular inclusions known as Lewy bodies, glial cytoplasmic inclusions, or neuronal processes, depending on the specific disease entity[@goedert2019]. The spectrum of alpha-synucleinopathies includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF)[@mccann2014].
Alpha-synuclein is a 140-amino acid protein encoded by the SNCA gene, predominantly expressed in presynaptic terminals of neurons throughout the brain[@burre2018]. Under physiological conditions, α-syn exists as a soluble, natively unfolded protein that participates in synaptic vesicle regulation, neurotransmitter release, and neuronal plasticity[@cabin2002]. However, in pathological states, α-syn undergoes a conformational transformation from its native unfolded state into beta-sheet-rich fibrillar aggregates that form the core constituent of disease-defining inclusions[@conway1998].
The clinical and pathological heterogeneity within the alpha-synucleinopathy spectrum reflects differences in the anatomical distribution of pathology, the cellular types affected (neurons versus glia), the structural conformation of the aggregated protein (distinct "strains"), and the presence or absence of co-pathologies such as beta-amyloid plaques or tau neurofibrillary tangles[@brundin2017]. Understanding the molecular mechanisms underlying this heterogeneity remains a central challenge in the field and has critical implications for diagnosis, biomarker development, and therapeutic intervention.
The alpha-synuclein protein comprises three distinct structural domains. The N-terminal domain (residues 1-60) contains repeats of the KTKEGV motif, which mediate membrane binding and are subject to pathogenic mutations (A53T, A30P, E46K)[@wood1999]. The central region (residues 61-95) encompasses the non-Aβ component (NAC) hydrophobic segment essential for aggregation. The C-terminal domain (residues 96-140) is highly acidic and may regulate synaptic vesicle trafficking[@davidson1998].
Under physiological conditions, α-syn exists as a soluble, intrinsically disordered protein that localizes to presynaptic terminals. Pathogenic mutations and post-translational modifications (phosphorylation at Ser129, ubiquitination, truncation) can accelerate aggregation into beta-sheet-rich fibrils that template further recruitment of endogenous α-syn in a prion-like manner[@luk2012]. These fibrils propagate between neurons and across brain regions in a pattern consistent with the [Braak staging hypothesis](/diseases/parkinsons-disease#braak-staging), beginning in the lower brainstem and olfactory bulb before spreading to the substantia nigra and cortical areas.
The aggregation process is influenced by cellular quality control systems including [autophagy](/mechanisms/autophagy)-[lysosomal pathway](/mechanisms/lysosomal-dysfunction) and the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system). Impairment of these systems, as occurs in [Parkinson's disease](/diseases/parkinsons-disease), leads to accumulation of toxic oligomers and fibrils[@brundin2017]. an N-terminal domain (residues 1-60) containing seven imperfect repeats of the sequence KTKEGV, a central hydrophobic NAC (non-Aβ component) region (residues 61-95) that constitutes the fibrillization core, and a C-terminal acidic tail (residues 96-140) rich in proline and acidic residues[@uversky2003]. The N-terminal domain mediates membrane association and can adopt an alpha-helical conformation upon binding to synaptic vesicles, while the NAC region is directly responsible for protein-protein interactions driving aggregation[@davidson1998].
The pathological aggregation of α-syn proceeds through a nucleation-dependent process in which monomers first form oligomeric intermediates (protofibrils) that subsequently elongate into mature fibrils[@wood1999]. These fibrils adopt a characteristic cross-beta sheet structure that is the defining feature of disease-associated inclusions. Critically, the fibrillar aggregates can templates the conversion of additional native α-syn molecules into the fibrillar form, enabling prion-like propagation between cells and brain regions[@luk2012].
Multiple post-translational modifications influence α-syn aggregation kinetics and the properties of the resulting aggregates. Phosphorylation at serine 129 (S129) is the most prevalent modification in pathological α-syn, found in over 90% of Lewy body inclusions in human brain tissue[@fujiwara2002]. This modification promotes fibril formation and serves as a sensitive biomarker for disease diagnosis. Additional modifications including ubiquitination, nitration, sumoylation, and truncation further modulate aggregation and cellular toxicity[@oueslati2022].
Emerging evidence demonstrates that α-syn aggregates exist in multiple distinct conformational strains that correlate with clinical phenotypes[@peelaerts2015]. MSA-derived fibrils exhibit different structural properties compared to PD/DLB-derived fibrils, as demonstrated by cryo-electron microscopy studies revealing distinct fold patterns[@schweighauser2022]. These strain differences appear to determine the pathological and clinical characteristics of the resulting disease, including the cellular tropism (neurons versus oligodendrocytes), anatomical distribution, and progression pattern.
The strain concept has important implications for understanding disease heterogeneity and developing targeted therapeutics. A given strain may be more susceptible to particular small molecule inhibitors or antibodies, suggesting the possibility of personalized treatment approaches based on the specific strain present in individual patients[@bidinosti2020].
The aggregation of α-syn triggers multiple downstream pathogenic mechanisms that collectively lead to neuronal dysfunction and death. Mitochondrial dysfunction represents a central mechanism, with α-syn directly interacting with mitochondrial complex I to impair its activity and increase reactive oxygen species generation[@liu2021]. Additionally, α-syn accumulation disrupts mitochondrial dynamics by altering the balance of fission and fusion proteins, leading to accumulation of dysfunctional mitochondria[@chinta2014].
Endoplasmic reticulum stress is another key consequence of α-syn pathology. The unfolded protein response is activated in neurons containing Lewy bodies, and chronic ER stress can trigger apoptosis through CHOP-mediated signaling pathways[@colla2012]. Furthermore, α-syn accumulation disrupts ER-Golgi trafficking, impairing protein maturation and secretion.
Neuroinflammation accompanies α-syn pathology in all alpha-synucleinopathies. Activated microglia surround areas of pathology, producing pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6[@gerhard2006]. This chronic inflammatory state accelerates neurodegeneration and may be triggered by extracellular α-syn recognition through pattern recognition receptors such as TLR2 and TLR4 on microglia and astrocytes[@braud2012].
[Parkinson's disease](/diseases/parkinsons-disease) is the most common alpha-synucleinopathy, affecting approximately 6-10 million individuals worldwide[@dorsey2005]. The core motor features—resting tremor, bradykinesia, rigidity, and postural instability—result from progressive degeneration of dopaminergic neurons in the [substantia nigra pars compacta](/brain-regions/substantia-nigra) and the consequent depletion of striatal dopamine[@jankovic2008]. The pathological hallmark is the presence of Lewy bodies (intracytoplasmic inclusions containing filamentous α-syn) and Lewy neurites (abnormal neuritic processes with α-syn deposits) throughout the nervous system[@spillantini1998].
The progression of Lewy body pathology follows a characteristic pattern ascending from the brainstem and olfactory bulb to the midbrain and ultimately to the limbic system and neocortex in advanced disease[@braak2002]. This progression correlates with the emergence of non-motor symptoms including anosmia, constipation, REM sleep behavior disorder, and autonomic dysfunction, which often precede motor symptoms by years or decades[@postuma2015].
[Dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies) accounts for 10-15% of all dementia cases and represents the second most common neurodegenerative dementia after [Alzheimer's disease](/diseases/alzheimers)[@vann2014]. DLB is characterized by progressive cognitive decline with prominent fluctuations, visual hallucinations, and parkinsonism[@mckeith1996]. Core diagnostic features include cognitive fluctuations with pronounced variations in attention and alertness, well-formed visual hallucinations typically occurring early in the disease course, and spontaneous parkinsonism[@mckeith2017].
Pathologically, DLB is defined by the presence of diffuse cortical Lewy bodies, often with lesser severity of nigrostriatal degeneration compared to [Parkinson's disease](/diseases/parkinsons-disease)[@gomperts2016]. A key distinguishing feature is the frequent co-occurrence of Alzheimer's disease pathology (beta-amyloid plaques and tau neurofibrillary tangles) in DLB, which may influence clinical presentation, treatment response, and disease progression[@irwin2017].
[Multiple system atrophy](/diseases/multiple-system-atrophy) is a sporadic, adult-onset disorder presenting with varying combinations of parkinsonian features, cerebellar ataxia, and autonomic failure[@gilman2008]. Two major clinical subtypes are recognized: MSA-P with predominant parkinsonian features and MSA-C with predominant cerebellar ataxia. Autonomic dysfunction—including orthostatic hypotension, urinary urgency/incontinence, and erectile dysfunction—is a required feature for diagnosis[@wenning2004].
Pathologically, MSA is characterized by extensive glial cytoplasmic inclusions (GCIs) in oligodendrocytes throughout the central nervous system, particularly in the [basal ganglia](/brain-regions/basal-ganglia), brainstem, cerebellum, and spinal cord[@gai1998]. These inclusions contain aggregated α-syn arranged in a fibrillar or tubular pattern distinct from the filaments found in Lewy bodies, reflecting the fundamental difference in strain between MSA and [PD](/diseases/parkinsons-disease)/DLB[@ozawa2004].
Pure autonomic failure presents with orthostatic hypotension and other autonomic disturbances without the motor or cognitive impairment characteristic of other alpha-synucleinopathies[@kaufmann2010]. Pathologically, it may represent the peripheral-only manifestation of synucleinopathy, with Lewy bodies confined to autonomic ganglia and peripheral nerves. However, a significant proportion of patients with PAF go on to develop PD or DLB over time, suggesting a common underlying pathogenic mechanism[@singer2016].
Dominantly inherited mutations in the [SNCA](/genes/snca) gene cause familial parkinsonism with typical Lewy body pathology. The Ala53Thr (A53T) mutation was first identified in the large Contursi kindred and causes early-onset, rapidly progressive [Parkinson's disease](/diseases/parkinsons-disease)[@polymeropoulos1997]. Additional pathogenic mutations including Ala30Pro, Glu46Lys, His50Gln, and Gly51Asp have been identified, each with distinct clinical characteristics[@hardy2010].
[SNCA](/genes/snca) gene multiplications demonstrate that wild-type α-syn overexpression is sufficient to cause neurodegeneration. Duplications cause typical late-onset PD, while triplications cause more severe early-onset disease with rapid progression, indicating a dose-dependent relationship between α-syn levels and disease severity[@singleton2003].
Genome-wide association studies have consistently identified the SNCA region as the strongest genetic determinant of sporadic [Parkinson's disease](/diseases/parkinsons-disease) risk[@nalls2019]. Common variants in the SNCA promoter, particularly the Rep1 microsatellite polymorphism and the single nucleotide polymorphism rs356219, influence α-syn expression levels and disease risk[@fuchs2008].
Additional genetic risk factors include variants in genes encoding proteins involved in lysosomal and autophagy pathways, including [GBA](/genes/gba) (glucocerebrosidase) and [LRRK2](/genes/lrrk2) (leucine-rich repeat kinase 2)[@woodside2021]. These findings support the importance of protein clearance mechanisms in α-syn pathogenesis and highlight potential therapeutic targets.
The diagnosis of alpha-synucleinopathies relies on clinical assessment emphasizing the distinctive symptom profiles of each disorder. Parkinson's disease requires bradykinesia plus at least one additional motor sign (resting tremor, rigidity, or postural instability)[@hughes1992]. DLB diagnosis requires cognitive decline plus two of three core features: visual hallucinations, parkinsonism, or cognitive fluctuations[@mckeith2010]. MSA diagnosis requires autonomic failure plus either parkinsonism (MSA-P) or cerebellar ataxia (MSA-C)[@quinn2007].
Several biomarker approaches are under active investigation for alpha-synucleinopathy diagnosis and disease tracking. Cerebrospinal fluid analysis reveals reduced total α-syn in PD/DLB patients, while phosphorylated α-syn is elevated[@mollenhauer2011]. The ratio of phosphorylated to total α-syn in CSF shows promise for distinguishing alpha-synucleinopathies from other neurodegenerative diseases[@kang2020].
Skin biopsy allows detection of phosphorylated α-syn in cutaneous nerve fibers, providing a minimally invasive approach for diagnosing peripheral synucleinopathy[@doppler2015]. This technique shows high sensitivity for detecting pathology in PD and may prove useful for monitoring disease progression or treatment response.
Dopamine transporter imaging using SPECT or PET ligands (such as [123I]FP-CIT or 18F-FP-CIT) demonstrates reduced striatal binding in PD, DLB, and MSA, reflecting presynaptic dopaminergic neuron loss[@brooks2004]. However, this approach cannot reliably distinguish between different alpha-synucleinopathies.
Structural MRI may reveal characteristic patterns of atrophy: posterior cortical and hippocampal atrophy in DLB, brainstem and cerebellar atrophy in MSA, and relatively preserved anatomy in early PD[@oba2005]. Advanced techniques including diffusion tensor imaging and resting-state functional MRI show alterations in white matter integrity and functional connectivity that may aid in differential diagnosis[@stoessl2019].
Levodopa remains the most effective treatment for motor symptoms in PD and MSA-P, though response in MSA is typically less robust and may be accompanied by earlier motor complications[@fahn2004]. Dopamine agonists, MAO-B inhibitors (selegiline, rasagiline, safinamide), and COMT inhibitors (entacapone, tolcapone) provide additional symptomatic benefit. Autonomic symptoms are managed with volume expansion strategies (fludrocortisone), compression garments, and midodrine[@jain2019].
Cognitive symptoms in DLB may respond to cholinesterase inhibitors such as donepezil and rivastigmine, though visual hallucinations may be exacerbated[@mckeith1992]. Care must be taken with antipsychotic medications, as patients with DLB are particularly sensitive to neuroleptic-induced parkinsonism and sedation.
Multiple therapeutic approaches target the fundamental α-syn aggregation process. Small molecule aggregation inhibitors including anle138b, SAR502250, and related compounds have shown efficacy in preclinical models and are advancing in clinical development[@sndermann2020]. These compounds are designed to prevent fibril formation or destabilize existing aggregates.
Immunotherapy approaches aim to clear extracellular α-syn or block its propagation. Active vaccination with PD01A (a synthetic α-syn peptide conjugate) has shown safety and immunogenicity in early-phase trials[@mandler2014]. Passive antibody approaches using monoclonal antibodies against α-syn (including prasinezumab and cinpanemab) are also in clinical development, with phase 2 trials ongoing[@pagano2024].
Several existing drugs show promise for repurposing in alpha-synucleinopathies based on preclinical data. The mucolytic agent [ambroxol](/therapeutics/ambroxol-parkinsons) increases glucocerebrosidase activity and reduces α-syn in cellular and animal models, and is being evaluated in clinical trials for [Parkinson's disease](/diseases/parkinsons-disease)[@mazzulli2011]. The anti-diabetic drug [metformin](/therapeutics/metformin-neurodegeneration) may activate AMPK and promote [autophagy](/mechanisms/autophagy)-mediated clearance of α-syn[@lu2020]. [Statins](/therapeutics/statins-neurodegeneration) and other [anti-inflammatory agents](/therapeutics/anti-inflammatory-therapy-neurodegeneration) represent additional repurposing candidates with plausible mechanisms[@gao2011].
Alpha-synucleinopathies represent a unified disease class linked by the pathological aggregation of alpha-synuclein protein. Despite significant clinical heterogeneity, the common molecular pathogenesis offers opportunities for disease-modifying therapies targeting aggregation, propagation, and clearance. Advances in understanding strain diversity, biomarker development, and therapeutic targeting hold promise for earlier diagnosis and more effective treatments for these devastating neurodegenerative disorders.